Doing Deals with Big Pharma September 23, 2010

From alliance to funding, Big Pharma and established biotech companies are increasingly investing in emerging companies. This Panel brings together executives from these larger companies to identify the type of deals now available to smaller companies, how to secure them, and how to manage them.

Questions that will be raised include:
* What are the best approaches for identifying a good partner?
* What type of partnerships are commonly used? And is your company a best candidate for a simple license, or a full blown joint venture, or a M&A?
* What about the rising of Big Pharma VC Funds?
* What are the strategies for attracting, securing and structuring strategic investments?
* How the Larger Bio-Companies' needs differ from VCs' needs?
* What are the key contract terms to be negotiated?
* What are the strategic reasoning behind different kinds partnerships?
* Effects on existing and potential future collaboration partners and other strategic decisions.
* Pros and cons of a small company partnering with a larger company.
* "Dos" and "don'ts" of managing these important relationships.

Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.

Speakers | Partial List
* Dr. Yael Weiss, Director of Licensing & External Research, Merck Research Laboratories, Merck & Co., Inc.
* Dr. David Donabedian, Vice President of Strategic Alliances, US ceedd, GlaxoSmithKline
* Sunil Patel , Vice President of Corporate Development
* Lead Moderator: Scott Iyama, Moderator, Orrick Herrington & Sutcliffe LLP

This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!

Official Website: http://www.sjbiocenter.com/event/ev_2010Q3-DoingDealsWithBigPharma.html